All lobbying filings

F. HOFFMANN-LA ROCHE LTD, AND ITS AFFILIATES

Lobbying for F HOFFMANN-LA ROCHE LTD AND ITS AFFILIATES

Filing 1st Quarter - Report

1st Quarter (Jan 1 - Mar 31) 2025 · District of Columbia · House · Senate · $130,000.00 expenses · posted Apr 16, 2025

Official filing document

Bills named in this filing 1

HR 1108
Diagnostics Testing Preparedness Plan Act of 2025

Lobbying activity 4

Health Issues

(HCR) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics

Medical/Disease Research/Clinical Labs

(MED) Issues related to public health emergency preparedness, including Pandemic All-Hazards Preparedness Act and H.R.1108 The Diagnostics Testing Preparedness Plan Act. Issues related to the FDA regulation of diagnostics. Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics

Medicare/Medicaid

(MMM) Clinical Lab Fee Schedule reform and Medicare coverage of FDA approved breakthrough diagnostics and innovative diagnostics (preeclampsia)

Foreign Relations

(FOR) PEPFAR Reauthorization / FY2026 Appropriations for PEPFAR laboratory services and testing

Source: federal Lobbying Disclosure Act filing. Bills are parsed from the activity descriptions.